Key points from article :
Unity Biotechnology announced 12- and 18-week data from its Phase 2 BEHOLD study of UBX1325
UBX1325 is a senolytic Bcl-xL inhibitor, in patients with diabetic macular edema (DME).
The study provided evidence of safety, visual acuity improvement and structural stability in a difficult-to-treat patient population.
“We have achieved a strong proof of concept for UBX 1325, a senolytic approach ... other diseases,” said Anirvan Ghosh, CEO.
UBX1325 is studied for age-related diseases of the eye, including
- diabetic macular edema (DME)
- age-related macular degeneration (AMD)
- diabetic retinopathy (DR)
Targeting Bcl-xL with UBX1325 eliminated senescent cells from diseased tissue while sparing cells in healthy tissue.
The 12- and 18-week BEHOLD results proved to be impressive.
“A treatment ... improvement in BCVA and stability of CST while also reducing the frequency of injections, huge value for patients with DME”, said Arshad Khanani, director at Sierra Eye Associates.
